Category

• Pipeline2
• Events1

Organizations

• Bausch + Lomb46
• Eyes On Eyecare33
• American Optometric Association25
• Alcon, Inc.23
• Glaukos20
• Harrow20
• Aldeyra Therapeutics16
• Ocuphire Pharma16
• Sight Sciences16
• American Academy Of Ophthalmology15

Tags

• Retina3
• FDA2
• Cell Therapy2
• Inherited Retinal Disease2
• Ophthalmology Tech Forum1
• Clinical Trials1
• Cornea1
• Genetic Testing1
• Macular1
• Ocular Implants1

• organizations:Neurotech Pharmaceuticals✕

Clear all

Pipeline

FDA extends Neurotech's BLA PDUFA date for MacTel therapy

Review period of NT-501, an encapsulated cell therapy, now has a target date of March 2025.

Events

KOLs eye the future of genetic engineering and cell transplantation

Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.

Pipeline

Neurotech Pharma earns BLA priority review for MacTel cell therapy

Investigational ocular implant is designed to slow progression of gradual central vision deterioration in rare neurodegenerative retinal disease.